These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

721 related items for PubMed ID: 23725360

  • 1. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K.
    Am J Manag Care; 2013 Apr; 19(4):278-85. PubMed ID: 23725360
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S, Baxter DC, Limone B, Roberts MS, Coleman CI.
    J Med Econ; 2012 Apr; 15(6):1088-96. PubMed ID: 22583065
    [Abstract] [Full Text] [Related]

  • 3. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP, Martín-Medina P, Berenguer-Ruiz L, Pérez-Carmona N, Sanchez-Perez R, Polache-Vengud J, Feliu-Rey E.
    Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
    O'Day K, Meyer K, Miller RM, Agarwal S, Franklin M.
    J Med Econ; 2011 Aug; 14(5):617-27. PubMed ID: 21777161
    [Abstract] [Full Text] [Related]

  • 5. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 6. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A, Bianchi MR, Deotto L, Benedetti MD.
    Eur Neurol; 2014 May 17; 72(3-4):173-80. PubMed ID: 25226868
    [Abstract] [Full Text] [Related]

  • 7. An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy.
    Carruthers RL, Rotstein DL, Healy BC, Chitnis T, Weiner HL, Buckle GJ.
    Mult Scler; 2014 Sep 17; 20(10):1381-90. PubMed ID: 24852928
    [Abstract] [Full Text] [Related]

  • 8. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.
    Earnshaw SR, Graham J, Oleen-Burkey M, Castelli-Haley J, Johnson K.
    Appl Health Econ Health Policy; 2009 Sep 17; 7(2):91-108. PubMed ID: 19731967
    [Abstract] [Full Text] [Related]

  • 9. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS.
    J Neurol Sci; 2011 Dec 17; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [Abstract] [Full Text] [Related]

  • 10. [[Natalizumab therapy, 2013].
    Karácsony M, Bencsik K, Vécsei L.
    Ideggyogy Sz; 2014 Jul 30; 67(7-8):220-8. PubMed ID: 25509362
    [Abstract] [Full Text] [Related]

  • 11. Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.
    Hoepner R, Havla J, Eienbröker C, Tackenberg B, Hellwig K, Meinl I, Hohlfeld R, Gold R, Kümpfel T, Kleiter I.
    Mult Scler; 2014 Nov 30; 20(13):1714-20. PubMed ID: 24842961
    [Abstract] [Full Text] [Related]

  • 12. Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in The Netherlands.
    Heisen M, Treur MJ, van der Hel WS, Frequin ST, Groot MT, Verheggen BG.
    J Med Econ; 2012 Nov 30; 15(6):1149-58. PubMed ID: 22737996
    [Abstract] [Full Text] [Related]

  • 13. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, Duquette P, Girard M, Pucci E, Lechner-Scott J, Slee M, Fernandez-Bolanos R, Grand'Maison F, Hupperts R, Verheul F, Hodgkinson S, Oreja-Guevara C, Spitaleri D, Barnett M, Terzi M, Bergamaschi R, McCombe P, Sanchez-Menoyo J, Simo M, Csepany T, Rum G, Boz C, Havrdova E, Butzkueven H, MSBase Study Group.
    Ann Neurol; 2015 Mar 30; 77(3):425-35. PubMed ID: 25546031
    [Abstract] [Full Text] [Related]

  • 14. A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.
    Walker A, Watson C, Alexopoulos ST, Deniz B, Arnold R, Bates D.
    Curr Med Res Opin; 2014 Apr 30; 30(4):629-35. PubMed ID: 24289170
    [Abstract] [Full Text] [Related]

  • 15. Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis.
    Crespo C, Izquierdo G, García-Ruiz A, Granell M, Brosa M.
    Neurologia; 2014 May 30; 29(4):210-7. PubMed ID: 24161412
    [Abstract] [Full Text] [Related]

  • 16. Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden.
    Bergvall N, Tambour M, Henriksson F, Fredrikson S.
    J Med Econ; 2013 May 30; 16(3):349-57. PubMed ID: 23211038
    [Abstract] [Full Text] [Related]

  • 17. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E, Louapre C, Lubetzki C, Papeix C.
    Mult Scler; 2014 Apr 30; 20(4):505-9. PubMed ID: 24367037
    [Abstract] [Full Text] [Related]

  • 18. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
    Baldi E, Guareschi A, Vitetta F, Senesi C, Curti E, Montepietra S, Simone AM, Immovilli P, Caniatti L, Tola MR, Pesci I, Montanari E, Sola P, Granella F, Motti L, Ferraro D.
    Curr Med Res Opin; 2014 Sep 30; 30(9):1849-55. PubMed ID: 24831186
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
    O'Day K, Meyer K, Stafkey-Mailey D, Watson C.
    J Med Econ; 2015 Apr 30; 18(4):295-302. PubMed ID: 25422991
    [Abstract] [Full Text] [Related]

  • 20. [Current treatment of multiple sclerosis].
    Csépány T.
    Lege Artis Med; 2011 Feb 30; 21(2):97-104. PubMed ID: 21710707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.